Real-World Evidence of Differences in Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm between Adult E-Vapor Users and Adult Cigarette Smokers

Nicotine and Tobacco Research

Volumn 22, Issue 7, 2020, Pages 1114-1122

  Oliveri, Douglas ^a   Liang, Qiwei ^a   Sarkar, Mohamadi ^a  

^a Altria Client Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; 3 HYDROXYPROPYL MERCAPTURIC ACID; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 8 ISOPROSTAGLANDIN F2 ALPHA; BIOLOGICAL MARKER; CARBOXYHEMOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CIGARETTE SMOKING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; TOBACCO USE; URINE SAMPLING; VAPING; ADVERSE EVENT; ELECTRONIC CIGARETTE; EXPOSURE; HARM REDUCTION; METABOLISM; MIDDLE AGED; PREVENTION AND CONTROL; PSYCHOLOGY; SMOKE; SMOKING;

ADULT; AGED; BIOMARKERS; CIGARETTE SMOKING; CROSS-SECTIONAL STUDIES; ELECTRONIC NICOTINE DELIVERY SYSTEMS; FEMALE; HARM REDUCTION; HUMANS; INHALATION EXPOSURE; MALE; MIDDLE AGED; SMOKE; SMOKERS;

EID: 85086524558     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntz185     Document Type: Article

References (49)

1. U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
2. Colilla SA. An epidemiologic review of smokeless tobacco health effects and harm reduction potential. Regul Toxicol Pharmacol. 2010;56(2):197-211.
3. Fairchild AL, Lee JS, Bayer R, Curran J. E-cigarettes and the harmreduction continuum. N Engl J Med. 2018;378(3):216-219.
4. Gartner C, Hall W. The potential role of snus in tobacco harm reduction. Addiction. 2009;104(9):1586-1587.
5. Haziza C, de La Bourdonnaye G, Donelli A, et al. Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol tobacco heating system 2.2 for three months (Part 1). Nicotine Tob Res. 2020;22(4):539-548.
6. Timberlake DS, Nikitin D, Johnson NJ, Altekruse SF. A longitudinal study of smokeless tobacco use and mortality in the United States. Int J Cancer. 2017;141(2):264-270.
7. Abrams DB, Glasser AM, Pearson JL, et al. Harm minimization and tobacco control: Reframing societal views of nicotine use to rapidly save lives. Annu Rev Public Health. 2018;39:193-213.
8. Nutt DJ, Phillips LD, Balfour D, et al. Estimating the harms of nicotinecontaining products using the MCDA approach. Eur Addict Res. 2014;20(5):218-225.
9. Zeller M, Hatsukami D; Strategic Dialogue on Tobacco Harm Reduction Group. The strategic dialogue on tobacco harm reduction: A vision and blueprint for action in the US. Tob Control. 2009;18(4):324-332.
10. Gottlieb S, Zeller M. A nicotine-focused framework for public health. N Engl J Med. 2017;377(12):1111-1114.
11. Goniewicz ML, Gawron M, Smith DM, et al. Exposure to nicotine and selected toxicants in cigarette smokers who switched to electronic cigarettes: A longitudinal within-subjects observational study. Nicotine Tob Res. 2017;19(2):160-167.
12. Benowitz NL. Emerging nicotine delivery products. Implications for public health. Ann Am Thorac Soc. 2014;11(2):231-235.
13. Bhatnagar A, Whitsel LP, Ribisl KM, et al.; American Heart Association Advocacy Coordinating Committee, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research. Electronic cigarettes: A policy statement from the American Heart Association. Circulation. 2014;130(16):1418-1436.
14. Hajek P, Etter JF, Benowitz N, Eissenberg T, McRobbie H. Electronic cigarettes: Review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction. 2014;109(11):1801-1810.
15. Smith TT, Hatsukami DK, Benowitz NL, et al. Whether to push or pull? Nicotine reduction and non-combusted alternatives-Two strategies for reducing smoking and improving public health. Prev Med. 2018;117:8-14.
16. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23(2):133-139.
17. Wagner KA, Flora JW, Melvin MS, et al. An evaluation of electronic cigarette formulations and aerosols for harmful and potentially harmful constituents (HPHCs) typically derived from combustion. Regul Toxicol Pharmacol. 2018;95:153-160.
18. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: A randomised controlled trial. Lancet. 2013;382(9905):1629-1637.
19. Caponnetto P, Campagna D, Cibella F, et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: A prospective 12-month randomized control design study. PLoS One. 2013;8(6):e66317.
20. Carpenter MJ, Heckman BW, Wahlquist AE, et al. A naturalistic, randomized pilot trial of e-cigarettes: Uptake, exposure, and behavioral effects. Cancer Epidemiol Biomarkers Prev. 2017;26(12):1795-1803.
21. Cravo AS, Bush J, Sharma G, et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regul Toxicol Pharmacol. 2016;81(Suppl 1):S1-S14.
22. Goniewicz ML, Smith DM, Edwards KC, et al. Comparison of nicotine and toxicant exposure in users of electronic cigarettes and combustible cigarettes. JAMA Netw Open. 2018;1(8):e185937.
23. Hecht SS, Carmella SG, Kotandeniya D, et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob Res. 2015;17(6):704-709.
24. Polosa R, Morjaria JB, Prosperini U, et al. Health effects in COPD smokers who switch to electronic cigarettes: A retrospective-prospective 3-year follow-up. Int J Chron Obstruct Pulmon Dis. 2018;13:2533-2542.
25. Sarkar M, Muhammad-Kah R, Liang Q, et al. Evaluation of spot urine as an alternative to 24h urine collection for determination of biomarkers of exposure to cigarette smoke in adult smokers. Environ Toxicol Pharmacol. 2013;36(1):108-114.
26. Sarkar M, Kapur S, Frost-Pineda K, et al. Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies. Nicotine Tob Res. 2008;10(12):1761-1772.
27. Roethig HJ, Munjal S, Feng S, et al. Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine Tob Res. 2009;11(10):1216-1225.
28. Wang J, Liang Q, Mendes P, Sarkar M. Is 24 h nicotine equivalents a surrogate for smoke exposure based on its relationship with other biomarkers of exposure? Biomarkers. 2011;16(2):144-154.
29. Goniewicz ML, Havel CM, Peng MW, et al. Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3421-3425.
30. Liu J, Liang Q, Frost-Pineda K, et al. Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1760-1769.
31. Rodgman A, Perfetti T. The Chemical Components of Tobacco and Tobacco Smoke. Boca Rotan, FL: CRC Press, Taylor and Francis Group; 2009.
32. FDA US. Harmful and potentially harmful constituents in tobacco products and tobacco smoke; established list. Federal Register. 2012;77:20034-20037.
33. Kim J, Lee K, Kwon HJ, et al. Association between secondhand smoke in hospitality venues and urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol concentrations in non-smoking staff. Int J Environ Res Public Health. 2016;13:1101-1112.
34. Goniewicz ML, Smith DM. Are some E-cigarette users "blowing smoke"?: Assessing the accuracy of self-reported smoking abstinence in exclusive e-cigarette users. Nicotine Tob Res. 2019;21(5):699-700.
35. Round EK, Chen P, Taylor AK, Schmidt E. Biomarkers of tobacco exposure decrease after smokers switch to an e-cigarette or nicotine gum. Nicotine Tob Res. 2019;21(9):1239-1247.
36. Shahab L, Goniewicz ML, Blount BC, et al. Nicotine, carcinogen, and toxin exposure in long-term e-cigarette and nicotine replacement therapy users: A cross-sectional Study. Ann Intern Med. 2017;166(6):390-400.
37. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med. 2003;54:113-129.
38. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672-688.
39. Dourado VZ, Tanni SE, Vale SA, et al. Systemic manifestations in chronic obstructive pulmonary disease. J Bras Pneumol. 2006;32(2):161-171.
40. Milara J, Cortijo J. Tobacco, inflammation, and respiratory tract cancer. Curr Pharm Des. 2012;18(26):3901-3938.
41. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention; 2010.
42. Brown DW, Giles WH, Croft JB. White blood cell count: An independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol. 2001;54(3):316-322.
43. Charland SL, Malone DC. Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Curr Med Res Opin. 2010;26(2):365-375.
44. Flores L, Vidal M, Abian J, et al. The effects of smoking and its cessation on 8-epi-PGF2alpha and transforming growth factor-beta 1 in Type 1 diabetes mellitus. Diabet Med. 2004;21(3):285-289.
45. Palmer RM, Stapleton JA, Sutherland G, et al. Effect of nicotine replacement and quitting smoking on circulating adhesion molecule profiles (sICAM-1, sCD44v5, sCD44v6). Eur J Clin Invest. 2002;32(11): 852-857.
46. van der Plas A, Pouly S, de La Bourdonnaye G, et al. Influence of smoking and smoking cessation on levels of urinary 11-dehydro thromboxane B2. Toxicol Rep. 2018;5:561-567.
47. Forey BA, Fry JS, Lee PN, Thornton AJ, Coombs KJ. The effect of quitting smoking on HDL-cholesterol-a review based on within-subject changes. Biomark Res. 2013;1(1):26.
48. Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: Meta-analysis. BMJ. 2012;345:e4439.
49. L. Felber Medlin CTT, W. T. Ng, N. Lama, et al. A multicenter, multiregional study on biological and functional changes in healthy adult smokers during one year of continuous smoking abstinence. San Francisco, CA: Society for Research on Nicotine and Tobacco; 2019.